Variety of qualified individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be labeled as obtaining gentle or average sickness could possibly have a https://hemgenix83826.blogginaway.com/36474611/the-definitive-guide-to-hemgenix